Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
You may also be interested in...
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.
As wearable medical devices become increasingly common for more and more complex applications, developers are facing questions are about the industry’s direction and how they will protect consumers.